Granted Patent
B2
US 12,415,828 · App. 17/012,948 · Granted Sep 16, 2025
Modified oligonucleotides and methods for their synthesis
Inventors:
Dmitry Stetsenko (Hampshire, GB); Maxim Kupryushkin (Kemerovo, RU); Dmitrii Pyshnyi (Novosibirsk, RU)
Assignee:
NOOGEN LLC
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Modified oligonucleotides that contain one or more of the phosphate groups substituted at phosphorus and methods for their synthesis are disclosed.
Claims (20)
1. A compound having the structure of:
wherein:
X is selected from the 5′ end of a nucleoside or oligonucleotide, and
Y is selected from the 3′ end of a nucleoside or oligonucleotide.
2. The compound of claim 1 , wherein X is the 5′ end of an oligonucleotide.
3. The compound of claim 2 , wherein Y is the 3′ end of an oligonucleotide.
4. The compound of claim 1 , wherein the compound comprises phosphorothioate.
5. The compound of claim 1 , wherein the compound comprises a 2′-amino nucleotide, 2′-fluoro nucleotide, 2′-O-methyl nucleotide, 2′-O-β-methoxyethyl nucleotide, or a LNA nucleotide.
6. The compound of claim 2 , wherein Y is the 3′-end of a nucleoside.
7. The compound of claim 1 , wherein X is the 5′-end of a nucleoside.
8. The compound of claim 7 , wherein Y is the 3′-end of an oligonucleotide.
9. The compound of claim 7 , wherein Y is the 3′-end of a nucleoside.
10. The compound of claim 1 , wherein the compound comprises a 2′-amino nucleotide, a 2′-fluoro nucleotide, a 2′-O-methyl nucleotide, a 2′-O-allyl nucleotide, a 2′-O-β-methoxyethyl nucleotide, a LNA nucleotide, or a tricyclo-DNA nucleotide.
11. The compound of claim 1 , wherein the compound comprises a 2′-fluoro nucleotide, a 2′-O-methyl nucleotide, a 2′-O-allyl nucleotide, a 2′-O-β-methoxyethyl nucleotide, or a LNA nucleotide.
12. The compound of claim 1 , wherein the compound comprises a 2′-deoxyribose.
13. The compound of claim 1 , wherein the compound comprises a linkage selected from a natural phosphate, phosphorothioate, phosphorodithioate, boranophosphate, phosphotriester, phosphoramidate, and methylphosphonate.
14. The compound of claim 1 , wherein the compound comprises a linkage selected from a natural phosphate, phosphorothioate, and methylphosphonate.
15. The compound of claim 11 , wherein the compound comprises a linkage selected from a natural phosphate, phosphorothioate, and methylphosphonate.
16. The compound of claim 12 , wherein the compound comprises a linkage selected from a natural phosphate, phosphorothioate, and methylphosphonate.
17. The compound of claim 1 , wherein the oligonucleotide comprises phosphorodiamidate morpholino oligonucleotide or peptidic nucleic acid.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 12, 2025
From: STETSENKO, DMITRY; KUPRYUSHKIN, MAXIM; PYSHNYI, DMITRII
To: NOOGEN LLC
Reel/Frame 071998/0695 →
SECURITY INTEREST
Recorded Aug 12, 2025
From: NOOGEN LLC
To: WAVE LIFE SCIENCES LTD.
Reel/Frame 071998/0699 →
Priority Claims (1)
RU 2014134380
· Aug 22, 2014
· national
Continuity (2)
Continuation
15329764
References Cited (161)
US 3634555A
· Sherif
· 1972
[cited by applicant]
US 3769406A
· Anatol et al.
· 1973
[cited by applicant]
US 4154826A
· Rathgeb
· 1979
[cited by applicant]
RU 2115658C1
· 1998
[cited by applicant]
WO WO8909221A1
· 1989
[cited by applicant]
WO 1994002498A1
· 1994
[cited by applicant]
WO 2001015737A2
· 2001
[cited by applicant]
WO WO03002587A2
· 2003
[cited by applicant]
WO WO2006023880A2
· 2006
[cited by applicant]
WO WO2007059816A1
· 2007
[cited by applicant]
WO WO2008128686A1
· 2008
[cited by applicant]
WO 2008141799A1
· 2008
[cited by applicant]
WO 2009147368A1
· 2009
[cited by applicant]
WO WO2010064146A2
· 2010
[cited by applicant]
WO WO2011005761A1
· 2011
[cited by applicant]
WO WO2013012758A1
· 2013
[cited by applicant]
WO WO2014010250A1
· 2014
[cited by applicant]
WO WO2014012081A2
· 2014
[cited by applicant]
WO WO2015107425A2
· 2015
[cited by applicant]
WO 2018056871A1
· 2018
[cited by applicant]
WO 2018156056A1
· 2018
[cited by applicant]
WO 2018223056A1
· 2018
[cited by applicant]
WO 2019032607A1
· 2019
[cited by applicant]
WO 2019112485A1
· 2019
[cited by applicant]
WO 2019200185A1
· 2019
[cited by applicant]
WO 2019217784A1
· 2019
[cited by applicant]
WO 2020118246A1
· 2020
[cited by applicant]
WO 2020191252A1
· 2020
[cited by applicant]
Del Fresno et al., Substituted Guanidines: Introducing Diversity in Combinatorial Chemistry, 2000, Org. Lett. 2, 23, 3539-3542 (Year: 2000).
[cited by examiner]
S.L. Beaucage et al., “Deoxynucleoside Phosphoramidites—A New Class of Key Intermediates for Deoxypolynucleotide Synthesis,” Tetrahedron Lett., vol. 22, (1981), pp. 1859-1862.
[cited by applicant]
S.S. Jones et al., “The Protection of Uracil and Guanine Residues in Oligonucleotide Synthesis,” Tetrahedron Lett., vol. 22, No. 47, (1981), pp. 4755-4758.
[cited by applicant]
S.T. Crooke, “Progress in Antisense Technology: The End of the Beginning,” Methods Enzymol., vol. 313, (2000), pp. 3-45.
[cited by applicant]
SciFinder, American Chemical Society, CAS Registry No. 937803-19-5, (2021), 4 pages.
[cited by applicant]
SciFinder, American Chemical Society, CAS Registry No. 937803-20-8, (2021), 4 pages.
[cited by applicant]
Scott M. Hammond et al., “Post-Transcriptional Gene Silencing by Double-Stranded RNA,” Nature Reviews: Genetics, vol. 2, (Feb. 2001), pp. 110-119.
[cited by applicant]
Shi-Kang Xi et al., “Synthesis of the Bidentate Organophosphorus Compounds With an Urea Substituents,” Synth. Commun., 20(21), (1990), pp. 3295-3301.
[cited by applicant]
Susan M. Angell et al., , “Consistent gene silencing in transgenic plants expressing a replicating potato virus X RNA6,” The EMBO Journal, vol. 16, No. 12, (1997), pp. 3675-3684.
[cited by applicant]
Thomas Tuschl, “RNA Interference and Small Interfering RNAs,” ChemBioChem, 2, (2001), pp. 239-245.
[cited by applicant]
W.J. Stec et al., “Automated Solid-Phase Synthesis, Separation, and Stereochemistry of Phosphorothioate Analogues of Oligodeoxyribonucleotides,” J. Am. Chem. Soc., 106, (1984), pp. 6077-6079.
[cited by applicant]
W.O. Lin et al., “Synthesis and Preliminary Complexation Studies of Dialkylphosphorylthiourea and Guanidines,” Phosphorus, Sulfur, and Silicon, vol. 92, (1994), pp. 1-9.
[cited by applicant]
Wannian Zhang, Editor-in-chief, “Modern Drug Design,” Program Pharmaceutical Textbook for Higher Medical Schools Throughout China, China Medical Science and Technology Press, Beijing China, Dec. 2005, pp. 273 with Engli…
[cited by applicant]
Wenfang Xu, Editor-in-chief, “New Drug Design Principles and Methods,” China Medical Science and Technology Press, Beijing China, Aug. 1996, pp. 100 with English translation, 11 pages.
[cited by applicant]
Yongdong Su et al., “Neutral and Negatively Charged Phosphate Modifications Altering Thermal Stability, Kinetics of Formation and Monovalent Ion Dependence of DNA G-Quadruplexes,” Chem. Asian J., 14, (2019), pp. 1212-12…
[cited by applicant]
Yongdong Su et al., “The Importance of Phosphates for DNA G-Quadruplex Formation: Evaluation of Zwitterionic G-Rich Oligodeoxynucleotides,” ChemBioChem, 21, (2020), pp. 1-13.
[cited by applicant]
Yulia V. Skvortsova et al., “A New Antisense Phosphoryl Guanidine Oligo-2′-OMethylribonucleotide Penetrates Into Intracellular Mycobacteria and Suppresses Target Gene Expression,” frontiers in Pharmacology, vol. 10, Art…
[cited by applicant]
Z.J. Xu et al., “Use of DNAzymes for cancer research and therapy,” Chin. Sci. Bull., vol. 57, No. 26, (2012), pp. 3404-3408.
[cited by applicant]
“Sarepta Therapeutics Announces Positive Safety Results from Phase I Clinical Study of Marburg Drug Candidate,” http://mail.pipelinereview.com/index.php/2014021053402/DNA-RNA-and-Cells/Sarepta-Therapeutics-Announces-Pos…
[cited by applicant]
J. Summerton et al., “Morpholino Antisense Oligomers: Design, Preparation, and Properties,” Antisense Nucl. Acid Drug Dev., 7, (1997), pp. 187-195.
[cited by applicant]
J.E. McMurry, “The Cyanogen Azide Ring-Expansion Reaction,” J. Org. Chem., vol. 38, No. 16, (1973), pp. 2821-2827.
[cited by applicant]
J.E. Summerton, “Morpholinos and PNAs Compared,” Chapter 6 in “Peptide Nucleic Acids, Morpholinos and Related Antisense Biomolecules,” Christopher G. Janson et al., Editors, Kluwer Academic/Plenum Publishers, (2003), pp…
[cited by applicant]
J.F. Hau et al., “Octathymidylates Involving Alternating Neopentylphosphothiomotriester Linkages With Controlled Stereochemistry at the Modified P-Center,” Tetrahedron Lett., vol. 32, No. 22, (1991), pp. 2497-2498.
[cited by applicant]
J.F. Lee et al., “Aptamer therapeutics advance,” Curr. Opin. Chem. Biol., 10, (2006), pp. 282-289.
[cited by applicant]
K.N. Chi, , “A Phase I Pharmacokinetic and Pharmacodynamic Study of OGX-011, a 2′-Methoxyethyl Antisense Oligonucleotide to Clusterin, in Patients With Localized Prostate Cancer,” J. Natl. Cancer Inst., vol. 97, No. 17,…
[cited by applicant]
L. Du et al., “Progress toward therapy with antisense-mediated splicing Modulation,” Curr. Opin. Mol. Ther., 11(2), (2009), pp. 116-123.
[cited by applicant]
L.A. Cates, “Phosphorus-Nitrogen Compounds V. Some Guanidine and 2-Aminopyrimidine Derivatives,” J. Pharm. Chem., 55, (1966), pp. 966-969.
[cited by applicant]
L.V. Bezgubenko et al., “Phosphorus Halides Complexes with 4-Dimethylaminopyridine and N-Methylimidazole,” Russian Journal of General Chemistry, vol. 79, No. 5, (2009), pp. 9.
[cited by applicant]
M. A. Bazhenova “Study of the Staudinger Reaction and Reveal of Key Factors Affecting the Efficacy of Automatic Synthesis of Phosphoryl Guanidinic Oligonucleotide Analogs,” Russian Journal of Bioorganic Chemistry, vol. …
[cited by applicant]
M. Duca et al., “The triple helix: 50 years later, the outcome,” Nucl. Acids Res. vol. 36, No. 16, (2008), pp. 5123-5138.
[cited by applicant]
M. Egholm et al., “Peptide Nucleic Acids (PNA). Oligonucleotide Analogues with an Achiral Peptide Backbone,” J. Am. Chem. Soc., 114, (1992), pp. 1895-1897.
[cited by applicant]
M. Kitamura et al., “Direct Synthesis of Organic Azides from Primary Amines with 2-Azido-1,3-dimethylimidazolinium Hexafluorophosphate,” Eur. J. Org. Chem., (2011), pp. 458-462.
[cited by applicant]
M. S. Kupryushkin et al., “Phosphoryl Guanidines: A New Type of Nucleic Acid Analogues,” ACTA Naturae, vol. 6, No. 4 (23), (2014), pp. 16-18.
[cited by applicant]
M.A. Behlke, “Chemical Modification of siRNAs for In Vivo Use,” Oligonucleotides, 18, (2008) pp. 305-319.
[cited by applicant]
Maksim Aleksandrovich Bazhenov, Department of Molecular Biology, Novosibirsk State University, “Development of Effective Methods of Producing Functionalized Oligonucleotides,” (2016), 37 pages.
[cited by applicant]
Maksim Sergeevich Kupryushkin, “Production of Tetrasubstituted Diaminocarbenium Azides for Synthesis of Oligonucleotide Derivatives,” LBMKh IKhBFM of the Siberian Division of the Russian Academy of Sciences, Novosibirsk…
[cited by applicant]
Maria Galyamova et al., “NooGen” LLC, “New class of DNA and RNA analogues as a new antisense-based drug discovery platform,” AstraZeneca Skolkovo startup challenge 2018, 20 pages.
[cited by applicant]
Maxim Kupryushkin et al., “Dodecyl-Modified Oligodeoxyribonucleotides as Platform for Oligonucleotide Delivery Into Eukaryotic Cells,” ICBFM SB RAS Poster, (2017), 1 page.
[cited by applicant]
Maxim Kupryushkin et al., “Dodecyl-modified oligodeoxyribonucleotides as platform for oligonucleotide delivery into eukaryotic cells,” 13th Annual Meeting, Oligo Nucleotide Therapeutics Society, #057, pp. 5, 67.
[cited by applicant]
Maxim Kupryushkin et al., “Phosphoryl Guanidines A New Type of Nucleic Acid Analogues,” NooGen ICBFM SB RAS Presentation, (2016), 15 pages.
[cited by applicant]
Maxim Kupryushkin et al., “Phosphoryl Guanidines A New Type of Nucleic Acid Analogues,” NooGen ICBFM SB RAS Presentation, (2017), 19 pages.
[cited by applicant]
Maxim Kupryushkin et al., “Precision medicine: New innovative platform for development of RNA-targeted antisense drugs,” NooGen ICBFM SB RAS Presentation, (2017), 20 pages.
[cited by applicant]
Maxim Kupryushkin et al., “Some Properties of Phosphoryl Guanidine Oligonucleotide Analogues,” ICBFM SB RAS Poster, (2015), 1 page.
[cited by applicant]
Maxim S. Kupryushkin et al., “Phosphoryl Guanidines: a New Class of Uncharged Oligonucleotide Analogues With Remarkable Properties,” NooGen ICBFM SB RAS Poster, (2014), 1 page.
[cited by applicant]
Maxim S. Kupryushkin et al., “Phosphoryl Guanidines: A New Type of Nucleic Acid Analogues,” NooGen ICBFM SB RAS, Cepheid Presentation, (Dec. 7, 2014), 20 pages.
[cited by applicant]
Maxim S. Kupryushkin, “Phosphoryl guanidine oligonucleotides (PGO)—structural and functional features: And a little bit of its discovery,” Bavarian-Russian Conference “Chemistry meets Biomedicine,” (2019), 30 pages.
[cited by applicant]
Maxim S. Kupryushkin, “Antisense oligonucleotide gapmers containing phosphorylguanidinegroupsreverseMDR1 mediated multiple drug resistance of tumor cells,” Molecular Theory Nucleic Acids, vol. 27, (Mar. 2022), pp. 211-2…
[cited by applicant]
N. Jearawiriyapaisarn et al., “Sustained Dystrophin Expression Induced by Peptide-conjugated Morpholino Oligomers in the Muscles of mdx Mice,” Mol. Ther., 16(9), (2008), pp. 1624-1629.
[cited by applicant]
N. Mignet et al., “Zwitterionic oligodeoxyribonucleotide N34_P54 phosphoramidates: synthesis and properties,” Nucl. Acids Res., vol. 26, No. 2, (1998), pp. 431-438.
[cited by applicant]
N.D. Sinha et al., “Polymer support oligonucleotide synthesis XVIJI1.2: use of (-cyanoethyl-N, N-dialkylamino-/Nmorpholino phosphoramidite of deoxynucleosides for the synthesis of DNA fragments simplifying deprotection …
[cited by applicant]
N.G. Dolinnaya et al., “Site-directed modification of DNA duplexes by chemical ligation,” Nucl. Acids Res, vol. 16, No. 9, (1988), pp. 3721-3738.
[cited by applicant]
N.M. Bell et al., “Chemical Modification of Oligonucleotides for Therapeutic, Bioanalytical and other Applications,” ChemBioChem, 10, (2009), pp. 2691-2703.
[cited by applicant]
Natalia A. Lebedeva et al., “Design of a New Fluorescent Oligonucleotide-Based Assay for a Highly Specific Real-Time Detection of Apurinic/Apyrimidinic Site Cleavage by Tyrosyl-DNA Phosphodiesterase 1,” Bioconjugate Che…
[cited by applicant]
Nikita A. Kuznetsov et al., “New oligonucleotide derivatives as unreactive substrate analogues and potential inhibitors of human apurinic/apyrimidinic endonuclease APE1,” Molecular Biosystems, 12, (2016), pp. 67-75.
[cited by applicant]
Nikita A. Kuznetsov et al., “Pre-steady state kinetics of DNA binding and abasic site hydrolysis by tyrosyl-DNA phosphodiesterase 1,” Journal of Biomolecular Structure and Dynamics, vol. 35, No. 11, (2017), pp. 2314-232…
[cited by applicant]
Oleg V. Markov et al., “Transport Oligonucleotides—A Novel System for Intracellular Delivery of Antisense Therapeutics,” molecules, 25, 3663, (2020), 27 pages.
[cited by applicant]
Olivier Voinnet et al., “Systemic signalling in gene silencing,” Nature, vol. 389, (Oct. 9, 1997), pp. 553.
[cited by applicant]
P. Sazani et al., “Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs,” Nucl. Acids Res., vol. 29, No. 19, (2001), pp. 3965-3974.
[cited by applicant]
P.C. Zamecnik et al., “Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide,” Proc. Natl. Acad. Sci. USA, vol. 75, No. 1, (1978), pp. 280-284.
[cited by applicant]
P.E. Nielsen, “Sequence-selective targeting of duplex DNA by peptide nucleic acides,” Curr. Opin. Mol. Ther., 12(2), (2010), pp. 184-191.
[cited by applicant]
P.H. Seeberger et al., “2′-Deoxynucleoside Dithiophosphates: Synthesis and Biological Studies,” J. Am. Chem. Soc., 117, (1995), pp. 1472-1478.
[cited by applicant]
P.I. Alimov et al., “Derivatives of the Methyleneamide of Diethylphosphoric Acid,” Izv. Akad. Nauk SSSR, Ser. Khim., (1964), pp. 1889-1892.
[cited by applicant]
P.J.; Lindh et al., “Nucleoside H-Phosphonates. III. Chemical Synthesis of Oligodeoxyribonucleotides By the Hydrogenphosphonate Approach,” Tetrahedron Lett., vol. 27, No. 34, (1986), pp. 4051-4054.
[cited by applicant]
Phillip A. Sharp, “RNAi and double-strand Rna,” Genes & Development, 13, (1999), pp. 139-141.
[cited by applicant]
R.L. Letsinger et al., “Cationic Oligonucleotides,” J. Am. Chem. Soc., 110, (1988), pp. 4470-4471.
[cited by applicant]
R.W. Barnett et al., “Debenzoylation of N-Benzoylnucleoside Derivatives With Ethylenediamine-Phenol,” Tetrahedron Lett., vol. 22, (1981). pp. 991-994.
[cited by applicant]
Ravil R. Garafutdinov et al., “Data on multimerization efficiency for short linear DNA templates and phosphoryl guanidine primers during isothermal amplification with Bst exo-DNA polymerase,” Data in brief, 29, (2020) 1…
[cited by applicant]
Ravil R. Garafutdinov et al., “Prevention of DNA multimerization using phosphoryl guanidine primers during isothermal amplification with Bst exo-DNA polymerase,” Biochimie, 168, (2020), pp. 259-267.
[cited by applicant]
S.A. Vinores, “Pegaptanib in the treatment of wet, age-related macular degeneration,” Int. J. Nanomed., 1(3), (2006), pp. 263-268.
[cited by applicant]
Belikova et al., “Synthesis of Ribonucleosides and Diribo-Nucleoside Phosphates Containing 2-Chloro-Ethylamine and Nitrogen Mustard Residues,” Tetrahedron Letters No. 37, 1967, pp. 3557-3562, 6 pages.
[cited by applicant]
Jager et al., “Oligonucleotide N-Alkylphosphormidates: Synthesis and Binding to Polynucleotides,” Biochemistry vol. 27, 1988, pp. 7237-7246, 10 pages.
[cited by applicant]
Ohkubo et al., “O-Selectivity and Utility of Phosphorylation Mediated by Phosphite Triester Intermediates in the N-Unprotected Phosphoramidite Method,” J. Am. Chem. Soc. vol. 126, No. 35, 2004, pp. 10884-10896, 13 pages.
[cited by applicant]
Sekine et al., “Proton-Block Strategy for the Synthesis of Oligodeoxynucleotides without Base Protection, Capping Reaction, and P-N Bond Cleavage Reaction,” J. Org. Chem. vol. 68, 2003, pp. 5478-5492, 15 pages.
[cited by applicant]
Kurata et al., “Characterization of high molecular weight impurities in synthetic phosphorothioate oligonucleotides,” Bioorganic & Medicinal Chemistry Letters vol. 16, 2006, pp. 607-614, 8 pages.
[cited by applicant]
Lee et al., “Synthesis and SAR of sulfonyl- and phosphoryl amidine compounds as anti-resorptive agents,” Bioorganic and Medicinal Chemistry Letters vol. 20, 2010, pp. 541-545, 5 pages.
[cited by applicant]
Ohkubo et al., “A new strategy for the synthesis of oligodeoxynucleotides directed towards perfect O-selective internucleotidic bond formation without base protection,” Tetrahedron Letters vol. 45, 2004, pp. 363-366, 4 …
[cited by applicant]
Skaric et al., “The Homologation of 1-(2,3-Dihydroxypropyl)- into 1-(2,4-Dihydroxybutyl)-thymine,” Croatica Chemica Acta vol. 52, 1979, pp. 51-59, 9 pages.
[cited by applicant]
Skaric et al.,“Aliphatic Thymidine and Deoxyuridine Analogs,” Croatica Chemica Acta vol. 52, 1979, pp. 281-292, 12 pages.
[cited by applicant]
Pon et al., “Hydroquinone-O, O-diacetic acid (‘Q-linker’) as a replacement for succinyl and oxalyl linker arms in solid phase oligonucleotide synthesis,” Nucleic Acids Research vol. 25, No. 18, 1997, pp. 3629-3635, 7 pa…
[cited by applicant]
A. Jäger et al., “Synthesis of Deoxynucleoside Methylphosphonates via a Phosphonamidite Approach,” J. Tetrahedron Lett., vol. 25, No. 14, (1984), pp. 1437-1440.
[cited by applicant]
A. S. Levinaa et al., Structural and Functional Analysis of Biopolymers and Their Complexes, “Impact of Delivery Method on Antiviral Activity of Phosphodiester, Phosphorothioate, and Phosphoryl Guanidine Oligonucleotide…
[cited by applicant]
A.H. Hall et al., “High potency silencing by single-stranded boranophosphate siRNA,” Nucleic Acids Res., vol. 34, No. 9, (2006), pp. 2773-2781.
[cited by applicant]
A.I. Lamond et al., “Antisense oligonucleotides made of 2′-O-alkyIRNA: their properties and applications in RNA biochemistry,” FEBS Lett., vol. 325, No. 1,2, (1993), pp. 123-127.
[cited by applicant]
A.S. Levina et al., “Brain as a potential target for antisense oligonucleotide treatment of hypertensive disease. Experimental study on the hypertensive ISIAH rat strain,” Basic & Clinical Pharmacology & Toxicology, Abs…
[cited by applicant]
A.V. Markov et al., “Antiviral Activity of a New Class of Chemically Modified Antisense Oligonucleotides against Influenza A Virus,” vol. 45, No. 6, (2019), pp. 774-782.
[cited by applicant]
Alesya Fokinaa et al., “Analysis of new charge-neutral DNA/RNA analogues phosphoryl guanidine oligonucleotides (PGO) by gel electrophoresis,” Analytical Biochemistry, 555, (2018), pp. 9-11.
[cited by applicant]
Alexander A. Komzov et al., “Diastereomers of a mono-substituted phosphoryl guanidine trideoxyribonucleotide: Isolation and properties,” Biochemical and Biophysical Research Communications, 513, (2019), pp. 807-811.
[cited by applicant]
Alexander A. Lomzov et al., “124. Comparative physico chemical and biological studies of phosphorylguanidine oligonucleotide diasteriomers,” Book of Abstracts, Albany 2019: The 20th Conversation, (2019), pp. 76.
[cited by applicant]
Alexander A. Lomzov et al., “136. Structure and hybridization properties of phosphorylguanidine oligonucleotides,” Journal of Biomolecular Structure and Dynamics, vol. 37, Supplement, (2019), pp. 83-84.
[cited by applicant]
Alexander A. Lomzov, “Data for isolation and properties analysis of diastereomers of a mono-substituted phosphoryl guanidine trideoxyribonucleotide,” Data in brief, 25, 104148, (2019), 25 pages.
[cited by applicant]
Alexey S. Chubarov et al., “Allele-Specific PCR for KRAS Mutation Detection Using Phosphoryl Guanidine Modified Primers,” 10, 872, (2020), 14 pages.
[cited by applicant]
Alexey Vladyko et al., “Synthesis, Purification and Delivery Into Mammalian Cells of Phosphoryl Guanidine Oligonucleotides (PGO) With Either Dna or 2′-OME RNA Backbone,” ICBFM SB RAS Poster, (2015), 1.
[cited by applicant]
Andrew Fire et al., “Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans,” Nature, vol. 391, (Feb. 19, 1998), pp. 806-811.
[cited by applicant]
Andrew Fire, “RNA-triggered gene silencing,” Trends in Genetics, vol. 15, No. 9, (Sep. 1999), pp. 358-363.
[cited by applicant]
Anna Epanchintseva et al., “Non-covalent binding of nucleic acids with gold nanoparticles provides their stability and effective desorption in environment mimicking biological media,” Nanotechnology, 29, 355601, (2018),…
[cited by applicant]
Anna S. Pavlova et al., “Amphiphilic “Like-a-Brush” Oligonucleotide Conjugates with Three Dodecyl Chains: Self-Assembly Features of Novel Scaffold Compounds for Nucleic Acids Delivery,” nanomaterials, 10, 1948, (2020), …
[cited by applicant]
Anna S. Pavlova et al., “Short Communication: SDS-PAGE procedure: Application for characterization of new entirely uncharged nucleic acids analogs,” Electrophoresis, 39, (2018), pp. 670-674.
[cited by applicant]
B. Froehler et al., “Phosphoramidate analogues of DNA: synthesis and thermal stability of heteroduplexes,” Nucl. Acids Res., vol. 16, No. 11, (1988), pp. 4831-4839.
[cited by applicant]
B. Froehler, , “Synthesis of DNA via deoxynucleoside H-phosphonate intermediates,” Nucleic Acids Res., vol. 14, No. 13, (1986). pp. 5399-5407.
[cited by applicant]
B. Kokel et al., “Iminium-Activated Azides—New Reagents for the Transfer of Diazonium or Diazo Groups,” Chem. Int. Ed. Engl., vol. 19, No. 9, (1980), pp. 716-717.
[cited by applicant]
B. Pérez et al., “Present and future of antisense therapy for splicing modulation in inherited metabolic disease,” J. Inherit. Metabol. Disease, 33, (2010), pp. 397-403.
[cited by applicant]
B. Wu et al., “Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer,” Proc. Natl. Acad. Sci. USA, vol. 105, No. 39, (2008), pp. 14814-14819.
[cited by applicant]
B.M. Mellbye et al., “Cationic phosphorodiamidate morpholino oligomers efficiently prevent growth of
[cited by applicant]
B.M. Pâtureau, “Induction of RNase H Activity by Arabinose-Peptide Nucleic Acid Chimeras,” Bioconjugate Chem., 18, (2007), pp. 421-430.
[cited by applicant]
C. Wilson et al., “Building oligonucleotide therapeutics using non-natural chemistries,” Curr. Opin. Chem. Biol., 10, (2006), pp. 607-614.
[cited by applicant]
C.A. Stein et al., “Physicochemical properties of phosphorothioate oligodeoxynucleotides,” Nucl. Acids Res., vol. 16, No. 8, (1988), pp. 3209-3221.
[cited by applicant]
C.B. Reese et al., “Reaction Between 1-Arenesuphonyl-3-Nitro-1, 2, 4-Triazoles and Nucleoside Base Residues,” Tetrahedron Lett., vol. 21, (1980), pp. 2265-2268.
[cited by applicant]
C.M. Yamada et al., “Synthesis and Biochemical Evaluation of Phosphonoformate Oligodeoxyribonucleotides,” J. Am. Chem. Soc., 128, (2006), pp. 5251-5261.
[cited by applicant]
Craig Tuerk et al., “Systematic Evolution of Ligands by Exponential Enrichment: RNA Ligands to Bacteriophage T4 DNA Polymerase,” Science, vol. 249, (1990), pp. 505-510.
[cited by applicant]
D.L. Swenson et al., “Chemical Modifications of Antisense Morpholino Oligomers Enhance Their Efficacy against Ebola Virus Infection,” Antimicrob. Agents Chemother., 53, (2009), pp. 2089-2099.
[cited by applicant]
Darya Novopashina et al., Novel Peptide Conjugates of Modified Oligonucleotides for Inhibition of Bacterial RNase P, Frontiers in Pharmacology, vol. 10, Article 813, (Jul. 19, 2019), 21 pages.
[cited by applicant]
Dimitri Stetsenko, “A new oligonucleotide-based therapy for Duchenne muscular dystrophy,” ICBFM SB RAS Presentation, (2016), 11 pages.
[cited by applicant]
Dmitry A. Stetsenko et al., “Ex Siberia Semper Novi: Siberia Always Brings Us Something New: Phosphoryl Guanidines: New Chemical Analogues of Nucleic Acids,” Science First Hand, N2 (41), (Aug. 2015), 2 pages.
[cited by applicant]
Dmitry A. Stetsenko, “Phosphoryl Guanidines: A New Class of Oligonucleotide Analogues with Remarkable Properties,” XXI International Round Table on Nucleosides, Nucleotides and Nucleic Acids, Poznań, Poland, (Aug. 24-28…
[cited by applicant]
Douglas J. Dellinger et al., “Solid-Phase Chemical Synthesis of Phosphonoacetate and Thiophosphonoacetate Oligodeoxynucleotides,” J. Am. Chem. Soc., 125, (2003). pp. 940-950.
[cited by applicant]
E. Merki et al., “Antisense Oligonucleotide Directed to Human Apolipoprotein B-100 Reduces Lipoprotein(a) Levels and Oxidized Phospholipids on Human Apolipoprotein B-100 Particles in Lipoprotein(a) Transgenic Mice,” Cir…
[cited by applicant]
E. S. Dyudeeva et al., “Physicochemical Properties of the Phosphoryl Guanidine Oligodeoxyribonucleotide Analogs,” Russian Journal of Bioorganic Chemistry, vol. 45, No. 6, (2019), pp. 709-718.
[cited by applicant]
Elena Dmitrienko et al., “Surface modification of SOI-FET sensors for label-free and specific detection of short RNA analyte,” Nanomedicine (Lond.), 11:16 (2016), pp. 2073-2082.
[cited by applicant]
F.R. Atherton et al., “Studies on Phosphorylation. Part 11. The Reaction of Diallcyl Phosphites with Polyhalogen Compounds in Presence of Bases. A New Method for the Phosphorylation of Amines.,” J. Chem. Soc. (1945), pp…
[cited by applicant]
G.B. Mulamba et al., “Human Cytomegalovirus Mutant with Sequence-Dependent Resistance to the Phosphorothioate Oligonucleotide Fomivirsen (ISIS 2922),” Antimicrob. Agents Chemother., vol. 42, No. 4, (Apr. 1998), pp. 971-…
[cited by applicant]
G.V. Boyd et al., “Formation of 1,2,4-Triazinium 1-Imides from 4-Aryl-1-azido-1,3-bis(dimethylamino)-2-azabutenylium Salts: Heterocyclic N-Imides lacking Exocyclic Stabilisation,” J. Chem. Soc. Chem. Commun., (1985), pp…
[cited by applicant]
H. Kaur et al., “Perspectives on Chemistry and Therapeutic Applications of Locked Nucleic Acid (LNA),” Chem. Rev., 107, (2007), pp. 4672-4697.
[cited by applicant]
H. Krishna et al., “Alkynyl Phosphonate Dna: A Versatile “Click” able Backbone for DNA-Based Biological Applications,” J. Am. Chem. Soc., 134, (2012), 11618-11631.
[cited by applicant]
HaiFang Yin et al., “Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function,” Human Mol. Genetics, vol. 17, No. 24, (2008), pp. 3909-3918.
[cited by applicant]
Ilya S. Dovydenko et al., “A convenient solid phase approach to obtain lipophilic 5′-phosphoramidate derivatives of DNA and RNA oligonucleotides,” Nucleosides, Nucleotides and Nucleic Acids, 37:2, (2018), pp. 102-111.
[cited by applicant]
Ilya S. Dovydenko et al., “A convenient solid phase approach to obtain lipophilic phosphoramidate derivatives of DNA and RNA oligonucleotides,” Nucleosides, Nucleotides and Nucleic Acids, Electronic Supporting Informati…
[cited by applicant]
International Preliminary Report on Patentability mailed Mar. 9, 2017 in PCT/RU2014/000647, 7 pages.
[cited by applicant]
J. Mendell et al., “Eteplirsen for the Treatment of Duchenne Muscular Dystrophy,” Ann. Neurol., vol. 74, No. 5, (2013), pp. 637-648.
[cited by applicant]
J. Ruckman et al., “2′-Fluoropyrimidine RNA-based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF165),” J. Biol. Chem., vol. 273, No. 32, (Aug. 7, 1998), pp. 20556-20567.
[cited by applicant]
Pannecouque, C. et al., Synthesis, enzymatic stability and physicochemical properties of oligonucleotides containing a N-cyanoguanidine linkage, Tetrahedron, 50(24):7231-7246 (1994).
[cited by applicant]
Vandendriessche, F. et al., Synthesis, enzymatic stability and base-pairing properties of oligothymidylates containing thymidine dimers with different N-substituted guanidine linkages, J. Chem. Soc. Perk. Trans. 1, 14:1…
[cited by applicant]